Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.

Moreira, Raphael B; Debiasi, Marcio; Francini, Edoardo; Nuzzo, Pier V; Velasco, Guillermo De; Maluf, Fernando C; Fay, Andre P; Bellmunt, Joaquim; Choueiri, Toni K; Schutz, Fabio A

Moreira, Raphael B; Debiasi, Marcio; Francini, Edoardo; Nuzzo, Pier V; Velasco, Guillermo De; Maluf, Fernando C; Fay, Andre P; Bellmunt, Joaquim; Choueiri, Toni K; Schutz, Fabio A.

Afiliación

Moreira RB; Hospital Alemão Oswaldo Cruz/Grupo Oncoclinicas do Brasil, São Paulo, SP, Brazil.
Debiasi M; Latin American Cooperative Oncology Group, Partenon, Porto Alegre, Brazil.
Francini E; PUCRS School of Medicine, Porto Alegre, RS, Brazil.
Nuzzo PV; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Velasco G; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Maluf FC; University of Genoa, Genoa, Italy.
Fay AP; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Bellmunt J; Latin American Cooperative Oncology Group, Partenon, Porto Alegre, Brazil.
Choueiri TK; Centro Oncológico Antônio Ermírio de Moraes, Beneficencia Portuguesa de Sao Paulo, Sao Paulo, SP, Brazil.
Schutz FA; Latin American Cooperative Oncology Group, Partenon, Porto Alegre, Brazil.

Oncotarget ; 8(48): 84572-84578, 2017 Oct 13.

Article en En | MEDLINE | ID: mdl-29137449

Palabras clave

abiraterone; enzalutamide; meta-analysis; metastatic prostate cancer; toxicity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google